Puma Biotech (PBYI) Reports Q3 EPS of $0.17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
BofA/Merrill Lynch Downgrades Puma Biotechnology (PBYI) to Underperform
November 2, 2018 9:18 AM EDTBofA/Merrill Lynch analyst Ying Huang downgraded Puma Biotechnology (NASDAQ: PBYI) from Buy to Underperform with a price target of $25.00 (from $92.00).
The analyst cites weak Nerlynx sales for the dramatic reversal of opinion.
For an analyst ratings summary and ratings history... More
JPMorgan Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 5:55 AM EDTJPMorgan analyst Cory Kasimov downgraded Puma Biotechnology (NASDAQ: PBYI) from Neutral to Underweight with a price target of $23.00 (from $83.00).
The analyst is incrementally more negative citing the "significantly tempered" expectations on Nerlynx.
For an analyst ratings summary and ratings history on... More
Barclays Downgrades Puma Biotechnology (PBYI) to Underweight
November 2, 2018 4:32 AM EDTBarclays analyst Gena Wang downgraded Puma Biotechnology (NASDAQ: PBYI) from Equalweight to Underweight with a price target of $29.00 (from $72.00).
The analyst steps aside citing the Q3 revenue miss along with a lack of growth clarity on Nerlynx.
For an analyst ratings... More
